NTRA:NGS-Natera Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 135.12

Change

+1.15 (+0.86)%

Market Cap

USD 0.67B

Volume

2.50M

Analyst Target

USD 56.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Natera Inc is a diagnostics company with proprietary molecular and bioinformatics technology that it is deploying to change the management of genetic disease.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+3.71 (+0.87%)

USD 34.17B
ILMN Illumina Inc

-1.45 (-0.98%)

USD 23.86B
ICLR ICON PLC

-8.37 (-3.94%)

USD 18.82B
EXAS EXACT Sciences Corporation

+0.57 (+1.14%)

USD 13.02B
MEDP Medpace Holdings Inc

+1.13 (+0.31%)

USD 9.93B
RDNT RadNet Inc

-1.03 (-1.23%)

USD 5.00B
SHC Sotera Health Co

-0.22 (-1.42%)

USD 4.49B
GH Guardant Health Inc

+1.88 (+6.32%)

USD 3.53B
NEOG Neogen Corporation

-0.16 (-1.04%)

USD 3.13B
TWST Twist Bioscience Corp

-2.77 (-6.12%)

USD 2.66B

ETFs Containing NTRA

GNOG:LSE Global X Genomics & Biote.. 5.21 % 0.00 %

+0.05 (+0.48%)

USD 8.22M
GN0M:XETRA Global X Genomics & Biote.. 4.92 % 0.00 %

+0.07 (+0.48%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.92 % 0.00 %

-0.09 (0.48%)

USD 5.93M
CURE:XETRA VanEck Genomics and Healt.. 4.55 % 0.00 %

+0.31 (+0.48%)

N/A
CURG:LSE VanEck Genomics and Healt.. 4.30 % 0.00 %

+0.17 (+0.48%)

USD 5.12M
EKG First Trust Nasdaq Lux Di.. 4.18 % 0.00 %

-0.13 (0.48%)

USD 2.46M
ATFV Alger 35 ETF 4.07 % 0.00 %

+0.50 (+0.48%)

USD 0.03B
ARCG:LSE ARK Genomic Revolution UC.. 3.95 % 0.00 %

+2.80 (+0.48%)

USD 3.68M
ARKG:LSE ARK Genomic Revolution UC.. 3.95 % 0.00 %

+0.02 (+0.48%)

USD 3.68M
WBIO:LSE WisdomTree BioRevolution .. 2.98 % 0.00 %

+1.50 (+0.48%)

USD 3.87M
WDNA 2.90 % 0.00 %

N/A

N/A
WRNA:XETRA WisdomTree BioRevolution .. 2.87 % 0.00 %

+0.03 (+0.48%)

USD 2.77M
CURE:AU ETFS S&P Biotech ETF 2.52 % 0.00 %

-1.40 (0.48%)

USD 0.04B
FHH:CA First Trust AlphaDEX US H.. 2.43 % 0.77 %

-0.36 (0.48%)

CAD 0.01B
WDNA:LSE WisdomTree BioRevolution .. 2.31 % 0.00 %

-0.02 (0.48%)

N/A
FXH First Trust Health Care A.. 2.21 % 0.63 %

-0.07 (0.48%)

USD 1.19B
HTEC Robo Global® Healthcare .. 1.93 % 0.00 %

-0.09 (0.48%)

USD 0.06B
DOCG:LSE L&G Healthcare Breakthrou.. 1.91 % 0.00 %

-0.50 (0.48%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.91 % 0.00 %

-0.02 (0.48%)

USD 0.07B
XMLH:XETRA L&G Healthcare Breakthrou.. 1.87 % 0.00 %

+0.04 (+0.48%)

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 1.87 % 0.00 %

-0.11 (0.48%)

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.87 % 0.00 %

+0.03 (+0.48%)

USD 0.06B
2B78:F iShares Healthcare Innova.. 1.65 % 0.00 %

-0.05 (0.48%)

N/A
LABU Direxion Daily S&P Biotec.. 1.44 % 1.14 %

-2.08 (0.48%)

USD 0.99B
IS0R:XETRA iShares $ High Yield Corp.. 0.34 % 0.00 %

+0.28 (+0.48%)

USD 2.71B
VISM:AU Vanguard MSCI Internation.. 0.19 % 0.00 %

-0.81 (0.48%)

USD 0.29B
ZPRS:F SSgA SPDR ETFs Europe II .. 0.18 % 0.00 %

N/A

USD 0.83B
ZPRS:XETRA SPDR MSCI World Small Cap.. 0.18 % 0.00 %

+0.48 (+0.48%)

USD 0.83B
WOSC:SW SPDR® MSCI World Small C.. 0.18 % 0.00 %

-1.20 (0.48%)

USD 0.92B
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

-0.29 (0.48%)

USD 0.14B
BTEC 0.00 % 0.42 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

+0.03 (+0.48%)

USD 0.08B
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

+0.02 (+0.48%)

N/A
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

-0.02 (0.48%)

N/A
IS0R:F iShares High Yield Corpor.. 0.00 % 0.00 %

+0.46 (+0.48%)

N/A
FRTY Alger Mid Cap 40 ETF 0.00 % 0.00 %

+0.26 (+0.48%)

USD 0.06B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 115.71% 92% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 115.71% 92% A 95% A
Trailing 12 Months  
Capital Gain 159.25% 90% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 159.25% 90% A- 94% A
Trailing 5 Years  
Capital Gain 252.70% 94% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 252.70% 94% A 93% A
Average Annual (5 Year Horizon)  
Capital Gain 50.51% 78% C+ 87% B+
Dividend Return 50.51% 78% C+ 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 92.44% 36% F 23% F
Risk Adjusted Return 54.64% 94% A 81% B-
Market Capitalization 0.67B 93% A 95% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 18.36 7% 7%
Price / Cash Flow Ratio -62.18 95% 95%
Price/Free Cash Flow Ratio -26.80 95% 94%
Management Effectiveness  
Return on Equity -40.78% 57% 36%
Return on Invested Capital -40.41% 46% 25%
Return on Assets -14.18% 53% 30%
Debt to Equity Ratio 36.97% 52% 49%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector